• 26.0% growth in group sales to A$68.2m
• 25.3% growth in U.S. sales to A$51.7m
• 28.3% growth in Rest of World sales to A$16.5m
• NovoSorb MTX sales up 195.2% to A$6.2m

PolyNovo Limited (ASX: PNV) has reported strong financial results for the first half of fiscal year 2026, with group sales growing 26.0% to A$68.2m driven by robust performance in the U.S. and Rest of World markets. U.S. sales grew 25.3% to A$51.7m, while Rest of World sales increased 28.3% to A$16.5m. The company's NovoSorb MTX product also saw a significant 195.2% increase in sales to A$6.2m. PolyNovo's financial position remains strong, with A$29.2m in cash and cash equivalents and improved cash flow from operations. The company is fully resourced to support its PMA submission for NovoSorb BTM in the U.S. and continues to focus on geographic expansion, pipeline development, and leveraging its NovoSorb technology platform. PolyNovo's executive leadership team has been strengthened, and the board of directors brings extensive global medtech expertise to support the company's growth strategy.

PolyNovo expects to maintain its strong commercial momentum, with continued growth in its core NovoSorb BTM and NovoSorb MTX product lines. The company is fully resourced to support its PMA submission for NovoSorb BTM in the U.S., which is expected to unlock expanded access to U.S. burn centers and support the next phase of growth.

PolyNovo is focused on accelerating its global impact, with a strategic emphasis on geographic expansion, indication growth, technology platform development, and pipeline progress. The company is also exploring opportunities to further leverage and license its NovoSorb platform to expand applications and optimize value creation.